Brand Medications with Generic Alternatives Anticipated to be Approved in May

May 1, 2022

  • Alimta (pemetrexed) – for cancer
  • Banzel 100mg tablets (rufinamide) – for seizures
  • Velcade (bortezomib) – for cancer

Adverse reactions or quality problems experienced with the use of a recalled product can be reported to the FDA’s MedWatch Adverse Event Reporting Program online, by mail, or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.


Benefit Advisors & Employees - Want to know more?

Members: Please call the number on the back of your ID card or e-mail Clients: Contact your Client Relations Manager